Clinical Trial Update: Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis [Phase 3]

View source ↗

Summary

Phase 3 trial assessing Anti-Bet v 1 monoclonal antibodies for reducing symptoms of seasonal allergic rhinitis; study completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Conjunctivitis

Drugs mentioned

• Anti-Bet v 1 monoclonal antibodies (null)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Allergic Rhinitis, Conjunctivitis | Phase 3 | Status: COMPLETED | Results posted: 2022-10-27